NCT05294835 is a Phase 2 clinical trial of Ketamine in Depression, sponsored by TruDiagnostic.

Who is sponsoring NCT05294835?

NCT05294835 is sponsored by TruDiagnostic.

What drugs are being tested in NCT05294835?

Interventions in NCT05294835: Ketamine.

What condition does NCT05294835 study?

NCT05294835 studies Depression, Post Traumatic Stress Disorder.

Is NCT05294835 still recruiting?

NCT05294835 is currently status unknown. Last updated 8 September 2022.

Last reviewed 2022-09-08 · How we verify

NCT05294835

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine and Epigenetic Aging

Status unknown Phase 2 Last updated 8 September 2022

What this trial tests

Phase 2 trial testing Ketamine in Depression in 20 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	TruDiagnostic
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 April 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

Ketamine (ketamine) — full drug profile →

Conditions studied

Depression — all drugs for Depression →
Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →

Sponsor

TruDiagnostic — full company profile →

Who can join

Adults 18 to 64, any sex, with Depression or Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.
Singewald N, Sartori SB, Reif A, Holmes A. · · 2023 · cited 40× · PMID 36623804 · DOI 10.1016/j.neuropharm.2023.109418
Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study.
Dawson KL, Carangan AMJM, Klunder J, Carreras-Gallo N, et al · · 2025 · cited 1× · PMID 41173838 · DOI 10.1038/s41398-025-03683-y

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other TruDiagnostic trials

Trials by the same sponsor.

NCT05535608 — Targeting the Nine Hallmarks of Aging on DNA Methylation · Phase 2 · unknown
NCT05297019 — A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging · Phase 2, PHASE3 · unknown
NCT05297097 — The Impact of a Human Breast Milk Supplement on Epigenetic and Cellular Markers · Phase 2 · unknown
NCT04939155 — Methylation Effects of COV-19 Infection and Vaccinations · unknown
NCT04946383 — Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05294835 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TruDiagnostic
Last refreshed: 8 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05294835.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing